NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00086580,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",https://clinicaltrials.gov/study/NCT00086580,,COMPLETED,"This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). Patients who meet all eligibility criteria and sign the informed consent document may be entered on the study.",YES,B-Cell Chronic Lymphocytic Leukemia,BIOLOGICAL: FluCAM [Fludara + Campath]|BIOLOGICAL: fludarabine phosphate,"Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment, Progression-free survival was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease (PD) as determined by the treatment-blinded IRRP, or death due to any cause. Results are expressed in months., Up to 6 years","Participant Best Response to Treatment Assessed by the Independent Response Review Panel (IRRP), Participants were evaluated by the IRRP according to National Cancer Institute (NCI) 1996 response criteria. The best response observed during the study is summarized. Response categories include Complete Response (CR) with normal physical exam, marrow cells and blood values, Partial Response (PR) with a \>= 50% decrease from baseline in lymphocytes, lymphadenopathy and liver or spleen exam, Stable Disease (SD) without significant progression from baseline, or Progressive Disease (PD) with increased size/number of nodes, size of liver or spleen, increase in lymphocytes, aggressive histology., Up to 9 months|Kaplan-Meier Estimates of Overall Survival Time, Overall survival was defined as the time in days from the date of randomization to the date of death due to any cause plus 1 day for all participants. Results are stated in months., Up to 6 years|Kaplan Meier Estimates for Time to Disease Progression Assessed by the Independent Response Review Panel (IRRP), Time to disease progression was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease as determined by IRRP. Results are stated in months., Up to 6 years|Kaplan-Meier Estimates for Duration of Response Assessed by the Independent Response Review Panel (IRRP), Duration of response was analyzed for participants who achieved a complete response (CR) or partial response (PR) and was defined as the number of days from the first date of documented response to the date of progressive disease as determined by IRRP or death due to any cause. Results are stated in months., Up to 6 years|Kaplan-Meier Estimates for Time to Alternative Therapy, Time to alternative therapy was defined as the number of days from the date of randomization to the date of first alternative therapy for chronic lymphocytic leukemia (CLL) or death resulting from any cause. Participants who had not received alternative therapy as of the data cutoff date were censored at the last follow-up visit assessment date plus 1 day. Results are stated in months., Up to 6 years|Mean EQ-5D™ Index Scores to Measure Quality of Life at Baseline, EQ-5D™ is a trademark of the EuroQol Group. EQ-5D™ is a standardized instrument for use as a measure of health outcome. The questionnaire asks about health status along 5 dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression, which are rated at three possible levels (no problems, some problems, extreme problems). The score ranges from best (+1) to worst (-0.59)., Day 0 (baseline)|Mean EQ-5D™ Index Scores to Measure Quality of Life at End of Treatment, EQ-5D™ is a trademark of the EuroQol Group. EQ-5D™ is a standardized instrument for use as a measure of health outcome. The questionnaire asks about health status along 5 dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression, which are rated at three possible levels (no problems, some problems, extreme problems). The score ranges from best (+1) to worst (-0.59)., up to month 6 (end of treatment)|Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at Baseline, The EuroQol Visual Analogue Scale (EQ-VAS) was also used to capture the self-rating of current health status using a visual ""thermometer"" with the end points of 100 (best imaginable health state) at the top and zero (worst imaginable health state) at the bottom., Day 0 (baseline)|Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at End of Treatment, The EuroQol Visual Analogue Scale (EQ-VAS) was also used to capture the self-rating of current health status using a visual ""thermometer"" with the end points of 100 (best imaginable health state) at the top and zero (worst imaginable health state) at the bottom., up to month 6 (end of treatment)|Summary of Participants With Adverse Experiences (AEs), Number of participants with adverse events (AEs). AEs were graded by the investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and were assessed for relatedness to study treatment (4 point scale from 'not related' to 'definitely related'). Categories reported include participant counts for treatment-emergent AEs, AEs for infections, serious AEs, AEs causing discontinuation of study drug(s), and deaths. Related AEs for the combination arm can be related to either fludarabine or alemtuzumab., Up to 6 years|Mean Systemic Clearance (CL) of Fludarabine, Clearance of drug from plasma is affected by the absorption, distribution, metabolism and elimination of the drug. Mean systemic clearance of fludarabine is derived from plasma concentration versus time data., month 4 (cycle 4): first day of dosing (pre-dose, 0.5 hr end of infusion), second day of dosing (pre-dose, 0.5 hr end of infusion), third day of dosing (pre-dose, 0.25 hr, 0.5 hr end of infusion, 1,2,3,4,6,24,48,72 hr after start of fludarabine infusion)|Total Volume of Distribution (Vss) of Fludarabine, The total volume of distribution (Vss) is the apparent volume in which fludarabine is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Total volume of distribution (Vss) of fludarabine is derived from plasma concentration versus time data., month 4 (cycle 4): first day of dosing (pre-dose, 0.5 hr end of infusion), second day of dosing (pre-dose, 0.5 hr end of infusion), third day of dosing (pre-dose, 0.25 hr, 0.5 hr end of infusion, 1,2,3,4,6,24,48,72 hr after start of fludarabine infusion)|Area Under the Curve (AUC) of Fludarabine From (AUC 0-tau), AUC (0-tau) is the area under the plasma concentration curve for fludarabine over the dosage interval (tau)., month 4 (cycle 4): first day of dosing (pre-dose, 0.5 hr end of infusion), second day of dosing (pre-dose, 0.5 hr end of infusion), third day of dosing (pre-dose, 0.25 hr, 0.5 hr end of infusion, 1,2,3,4,6,24,48,72 hr after start of fludarabine infusion)|Maximum Plasma Concentration (Cmax) of Fludarabine, Cmax is the maximum plasma concentration of fludarabine observed., month 4 (cycle 4): first day of dosing (pre-dose, 0.5 hr end of infusion), second day of dosing (pre-dose, 0.5 hr end of infusion), third day of dosing (pre-dose, 0.25 hr, 0.5 hr end of infusion, 1,2,3,4,6,24,48,72 hr after start of fludarabine infusion)|Participants With Minimal Residual Disease (MRD), MRD negativity in this report was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. MRD was assessed in participants with a clinical complete response (CR) or partial response (PR) without recovery of blood counts. MRD represents a very positive outcome., up to 9 months","Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) for Participants With Rai Stage I-II, Progression-free survival was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease (PD) as determined by the treatment-blinded IRRP, or death due to any cause. Results are expressed in months and include participants with Rai stage I or II., Up to 6 years|Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) for Participants With Rai Stage III-IV, Progression-free survival was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease (PD) as determined by the treatment-blinded IRRP, or death due to any cause. Results are expressed in months and include participants with Rai stage III or IV., Up to 6 years|Kaplan-Meier Estimates of Overall Survival Time for Participants With Rai Stage I-II, Overall survival was defined as the time in days from the date of randomization to the date of death due to any cause plus 1 day for all participants. Results are stated in months and include participants with Rai Stage I or II., Up to 6 years|Kaplan-Meier Estimates of Overall Survival Time for Participants With Rai Stage III-IV, Overall survival was defined as the time in days from the date of randomization to the date of death due to any cause plus 1 day for all participants. Results are stated in months and include participants with Rai Stage III or IV., Up to 6 years","Genzyme, a Sanofi Company",,ALL,"ADULT, OLDER_ADULT",PHASE3,335,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CAM314|2004-000149-39,2004-07,2010-06,2010-06,2004-07-08,2011-08-11,2014-03-13,"Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|Medizinische Universitatsklinik Graz, Graz, 8036, Austria|Universitat Wien AKH, Innere Medizin I, Wien, 1090, Austria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven, 5800, Bulgaria|UMHAT St. Georgi, Hematology Clinic, Plovdiv, 4000, Bulgaria|Multiprofile Hospital for Active Treatment ""Alexandrovska"", Sofia, 1431, Bulgaria|National Center for Heamtology and Transfusiology, Sofia, 1756, Bulgaria|Multiprofile Hospital for Active Treatment, St. Marina, Varna, 9010, Bulgaria|Cancer Care Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Hopital Notre-Dame du CHUM, Montreal, Quebec, H2L 4M1, Canada|Clinical Hospital Center Rijeka, Department of Haematology, Rijeka, 51000, Croatia|Clinical Hospital Merkur, Zagreb, 10000, Croatia|University Hospital Dubrava, Zagreb, 10000, Croatia|CHRU - Hopital Claude Huriez, Lille, Cedex, 59037, France|Charite-Universitatsmedizin Berlin Campus Benjamin-Franklin, Berlin, 12203, Germany|Charite Universitatsklinikum der Humboldt-Universitat zu Berlin, Berlin, 13353, Germany|Klinikum der Universitat zu Koln, Klinik 1 fur Innere Medizin, Koln, 50924, Germany|Robert-Bosch Krankenhaus GmbH, Stuttgart, 70376, Germany|""Laikon"" General Hospital, University of Athens, Goudi, Athens, 11527, Greece|U.O. Oncologia Medica Azienda Ospedaliera ""Pugliese-Ciaccio"", Cantanzaro, 88100, Italy|Unita Operativa di Medicina Generale Reumatologia e Oncoematologia, Milano, 20132, Italy|Istituto di Ematologia Dipartmento di Biotechnologie Celluari ed Ematologia, Universita di Roma ""La Sapienza"", Rome, 00161, Italy|Klinika Hematologii i Transplantacji Szpiku, Katowice, 40-027, Poland|Klinika Hematologii AM, Lodz, 93-513, Poland|Klinika Hematologii Pomorskiej Akademii Medycznej w Szczecinie, Szczecin, 71-252, Poland|Katedra i Klinika Hamatologii, Onkologii I Chorob Wewnetrznych AM, Warszawa, 02-097, Poland|Klinika Hematologii, Nowotworow Krwii 1 Transplantacji Szpiku, Wroclaw, 50-367, Poland|Hospital de Santa Maria Servico de Hematologia Clinica/Hospital de dia de Hematologia, Lisboa, 1649-035, Portugal|Hospital de Sao Teotonio, Servico de Hematologia/Hosptial de Dia Oncologico, Viseu, 3504-509, Portugal|Institutol Clinic Fundeni, Clinica Heamtologie, Bucharest, 022328, Romania|State Healthcare Department ""Sverdlovsk Regional Clinical Hospital #1"",, Ekaterinburg,, 620102, Russian Federation|GU ""Main Military Clinical Hospital named after acad. N.N.Burdenko of MO of Russia"", Haematology Centre 3, Moscow, 105229, Russian Federation|GOUVPO ""Saint-Petersburg State Medical University named after acad I.P.Pavlov of Roszdrav"", Bone Marrow Transplantology Clinic, Saint-Petersburg, 197089, Russian Federation|Saint-Petersburg GUZ ""City Hospital #31"" 3, Dynamo Prospect, Saint-Petersburg, 197110, Russian Federation|University Hospital, Dept. of Hematology, Lund, 221 85, Sweden|Orebro University Hospital, Dep. of Medicine, Orebro, 701 85, Sweden|Universitetssjukhuset, Orebro, 701 85, Sweden|Medicin kliniken/Hematologsektionen, Sundsvall, 851 86, Sweden|Akademiska sjukhuset, Uppsala, 751 85, Sweden|Cherkasskly Oncology Dispensary, Cherkasy, 79044, Ukraine|City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, 49102, Ukraine|Donetsk State Medical University, Donetsk, 83045, Ukraine|Kharkov Regional Clinical Oncology Center, Department of Hematology, Kharkov, 61070, Ukraine|Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, 29000, Ukraine|Institute of Oncology AMS of Ukraine, Kiev, 03022, Ukraine|Institute of Hematology and Transfusiology AMS of Ukraine, City Clinical Hospital #9, Kiev, 04112, Ukraine|Scientific Centre for Radiation Medicine AMS of Ukraine, Dept of Hematology and Transplantology, Kyiv, 03115, Ukraine|Lviv National Medical University named Danilo Galytcky, Lviv, 79044, Ukraine",
